Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.44 |
| ▸ | SLC34A1 | Q06495 | 4/20 | 0.40 |
| ▸ | RXRA | P19793 | 3/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.36 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4230109 | 0.89 | AR (0.56) | ARP2RX7SLC34A1SMO | |
| SCHEMBL4239402 | 0.88 | AR (0.55) | ARP2RX7SLC34A1SMO | |
| SCHEMBL4240586 | 0.86 | AR (0.49) | ARP2RX7SLC34A1SMO | |
| SCHEMBL4237912 | 0.86 | AR (0.56) | AR | |
| SCHEMBL4234391 | 0.86 | AR (0.53) | ARP2RX7SLC34A1SMO | |
| SCHEMBL4305589 | 0.85 | AR (0.54) | ARSLC34A1SMO | |
| SCHEMBL4233150 | 0.85 | AR (0.60) | ARSLC34A1SMO | |
| SCHEMBL4233511 | 0.84 | AR (0.70) | ARP2RX7SLC34A1SMO | |
| SCHEMBL4240687 | 0.83 | AR (0.52) | ARSLC34A1 | |
| SCHEMBL4296323 | 0.83 | AR (0.54) | ARSLC34A1SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009119880-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009119880-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | CBR3, CBR1, NOX5 | AR 622/4885P2RX7 681/4885SLC34A1 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.